Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · IEX Real-Time Price · USD
+0.020 (0.87%)
At close: May 23, 2024, 4:00 PM
-0.040 (-1.72%)
After-hours: May 23, 2024, 7:11 PM EDT

Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides.

The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.

Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals logo
Country United States
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Nadav Kidron Esq.

Contact Details

1185 Avenue Of The Americas, 3rd Floor
New York, New York 10036
United States
Phone 646-844-1164
Website oramed.com

Stock Details

Ticker Symbol ORMP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001176309
CUSIP Number 68403P203
ISIN Number US68403P2039
Employer ID 98-0376008
SIC Code 2834

Key Executives

Name Position
Nadav Kidron Esq. President, Chief Executive Officer and Executive Chairman
David Silberman CPA Chief Financial Officer and Treasurer
Dr. Miriam Kidron Ph.D. Chief Scientific Officer and Director
Joshua Hexter Chief Operating and Business Officer

Latest SEC Filings

Date Type Title
May 13, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 6, 2024 8-K Current Report
Mar 22, 2024 SC 13D General statement of acquisition of beneficial ownership
Mar 19, 2024 8-K Current Report
Mar 18, 2024 8-K Current Report
Mar 18, 2024 8-K Current Report
Mar 18, 2024 424B5 Filing
Mar 6, 2024 10-K Annual Report
Feb 20, 2024 8-K Current Report